Improved in vivo protein expression and durability using dbDNA™ delivered by Sartorius Polyplus non-viral delivery solutions
This application note evaluates the in vivo performance of Touchlight’s doggybone DNA™ (dbDNA™) compared with conventional plasmid DNA when delivered using Sartorius Polyplus non‑viral delivery reagents. The study investigates how dbDNA influences protein expression levels and durability across multiple tissues following both intravenous and intramuscular administration in mouse models.
Using luciferase as a reporter, the authors compare dbDNA and plasmid DNA formulated with in vivo‑jetPEI® and in vivo‑jetRNA®+. Results show that dbDNA consistently forms smaller delivery complexes and achieves higher and more sustained protein expression in key organs, including lung, spleen, and muscle. Readers will learn how dbDNA performs in combination with polymer‑ and lipid‑based non‑viral delivery reagents, how delivery route and formulation affect biodistribution, and why dbDNA may offer advantages for applications such as non‑viral gene therapy and DNA‑based vaccines requiring robust and durable transgene expression.
Download the application note to explore the experimental design, in vivo data, and detailed performance comparisons between dbDNA and plasmid DNA delivered using Sartorius Polyplus technologies.
